| ABSTRACT | 第4页 |
| 摘要 | 第5-6页 |
| DEDICATION | 第6-7页 |
| ACKNOWLEDGMENTS | 第7-11页 |
| 1. Introduction | 第11-14页 |
| 2. Literature Review | 第14-19页 |
| 2.1 Medicine and its Feature as a Commodity | 第14-15页 |
| 2.2 Previous Studies on Pharmaceutical Price Policies in China | 第15-17页 |
| 2.3 Previous Studies on the Supply Distribution System | 第17-19页 |
| 3. Chinese Health System | 第19-31页 |
| 3.1 Government Stakeholders in the Healthcare Sector | 第19-21页 |
| 3.2 Recent Healthcare Reforms(2009,to date) | 第21-22页 |
| 3.3 National Essential Medicines List NEML | 第22-24页 |
| 3.4 The Seleotion of Essential Medicines for the NEML | 第24-31页 |
| 4. The Chinese Pharmaceutical Market | 第31-48页 |
| 4.1 Medicines Supply System in China | 第37-41页 |
| 4.2 The Regulation of Drug Prices in China | 第41-43页 |
| 4.3 High Priced Pharmaceutical Cases in China | 第43-47页 |
| 4.4 China's Main Problems in the Chinese Pharmaceutical Sector | 第47-48页 |
| 5. The Italian Pharmaceutical System | 第48-55页 |
| 5.1 Pharmaceutical Supply Chain in Italy | 第49-50页 |
| 5.2 Drug Price Regulations in Italy | 第50-55页 |
| 6. Policy Options for China | 第55-59页 |
| 6.1. Comprehensive Selection of Essential Drugs | 第55页 |
| 6.2 Improved Supply Chain and Drug Pricing | 第55-56页 |
| 6.3 Prevention of the Asymmetric Iformation | 第56-57页 |
| 6.4 Separation between Medical Services and Pharmaceutical Sales | 第57页 |
| 6.5 Prohibition of Lobbying Practice in Drug Sales | 第57-59页 |
| 7. Conclusions | 第59-60页 |
| 8. Bibliography | 第60-63页 |
